Agendia

Empowering Early-Stage Breast Cancer Patients through Personalized Cancer Care

Every woman facing early-stage breast cancer deserves a chance at a long, healthy life. Agendia is excited to partner with Susan G. Komen to support women in their journey. We believe that understanding a cancer’s biology early on is key to a cancer-free life. Together with Susan G. Komen, we stand by women, their families, and care teams as they navigate the challenges of a cancer diagnosis. By uncovering the unique biology of each tumor early in the process, we aim to replace one-size-fits-all treatments with personalized care. This collaboration empowers women with information about their treatment, fostering shared decision-making and ensuring a tailored approach to guide them back to a life they know.

About Agendia:
Agendia is a leading provider of innovative solutions in the field of precision oncology. With a focus on early-stage breast cancer, Agendia offers reliable biological insights that inform personalized treatment decisions for patients and their care teams. Their advanced genomic assays, MammaPrint® and BluePrint®, enable clinicians to quickly identify the most effective treatment plan, minimizing the risk of both under and over-treatment.

Founded in 2003 in Amsterdam, Agendia is headquartered in Irvine, California with a state-of-the-art laboratory facility. Led by world-renowned scientists and oncologists, Agendia is committed to advancing genomic insights through ongoing research. This includes the notable FLEX Study– the world’s largest whole transcriptome Real-World Evidence-based Breast Cancer database which aims to revolutionize precision in breast cancer management. With cutting-edge technology, research, and innovation, Agendia strives to shape the future of precision oncology and make a significant impact in the fight against breast cancer.